Literature DB >> 16417605

The in vitro effects of piroxicam and meloxicam on canine cell lines.

C Knottenbelt1, G Chambers, E Gault, D J Argyle.   

Abstract

OBJECTIVES: To analyse the direct antiproliferative effects of both piroxicam and meloxicam at a variety of concentrations on a series of canine cancer cell lines and the mechanism of cell death.
METHODS: The in vitro effects of piroxicam and meloxicam at various concentrations on canine cell cultures (Madin-Darby canine kidney cells, osteosarcoma, mammary carcinoma, and lymphoma) were assessed with respect to proliferation inhibition and apoptosis induction. Western blot analysis of cyclooxygenase-1 and cyclooxygenase-2 expression was performed on all cell lines.
RESULTS: All cell lines used in this study were cyclooxygenase-1 and cyclooxygenase-2 positive apart from Madin-Darby canine kidney cells which were negative for both cyclooxygenase-1 and cyclooxygenase-2. Both meloxicam and piroxicam were able to inhibit proliferation in cell lines in a dose-dependent manner. However, the drug concentration required for a given effect was cell line dependent. CLINICAL SIGNIFICANCE: The results suggest that significant inhibition of proliferation and induction of apoptosis would only occur when drug concentrations were in excess of those that can be achieved in vivo following maximum recommended dose rates. It is possible, however, that local or topical treatment or altered dosing regimens may offer alternative approaches to the use of these drugs as antineoplastic agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417605     DOI: 10.1111/j.1748-5827.2006.00006.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  12 in total

1.  Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations.

Authors:  Vimon Tantishaiyakul; Krit Suknuntha; Visit Vao-Soongnern
Journal:  AAPS PharmSciTech       Date:  2010-05-29       Impact factor: 3.246

Review 2.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

3.  Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures.

Authors:  Vimon Tantishaiyakul; Sarunyoo Songkro; Krit Suknuntha; Pattakarn Permkum; Pattawee Pipatwarakul
Journal:  AAPS PharmSciTech       Date:  2009-06-12       Impact factor: 3.246

4.  Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.

Authors:  Carlos H de M Souza; Evandro Toledo-Piza; Renee Amorin; Andrigo Barboza; Karen M Tobias
Journal:  Can Vet J       Date:  2009-05       Impact factor: 1.008

5.  Piroxicam-induced hepatic and renal histopathological changes in mice.

Authors:  Hossam Ebaid; Mohamed A Dkhil; Mohamed A Danfour; Amany Tohamy; Mohamed S Gabry
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

6.  Cyclooxygenase 1 mRNA expression is undetectable in Madin Darby Canine Kidney cells.

Authors:  Guillaume Pelletier; Bhaja K Padhi
Journal:  BMC Res Notes       Date:  2015-03-24

7.  Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.

Authors:  María P Iturriaga; Rodolfo Paredes; Jose I Arias; Cristian G Torres
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

8.  Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.

Authors:  Edina Karai; Kornélia Szebényi; Tímea Windt; Sára Fehér; Eszter Szendi; Valéria Dékay; Péter Vajdovich; Gergely Szakács; András Füredi
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

9.  The effects of piroxicam and deracoxib on canine mammary tumour cell line.

Authors:  Fulya Ustün Alkan; Oya Ustüner; Tülay Bakırel; Suzan Cınar; Gaye Erten; Günnur Deniz
Journal:  ScientificWorldJournal       Date:  2012-11-07

10.  Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27.

Authors:  Tülay Bakirel; Fulya Üstün Alkan; Oya Üstüner; Suzan Çinar; Funda Yildirim; Gaye Erten; Utku Bakirel
Journal:  J Vet Med Sci       Date:  2016-01-29       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.